Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00350818 · ClinicalTrials.gov registry record · Phase 1
Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT)
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
NCT00350818: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00350818 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 90 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00350818, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
Study Summary
Primary Objective: -To determine the dose and schedule combination of 5-Azacitidine, when used as maintenance treatment after allogeneic transplantation for high-risk AML / MDS. Secondary Objective: -To assess the effect of treatment on survival after allogeneic transplantation for high-risk AML / MDS.
Interventions
- DRUG Azacitidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2005-10 |
| Est. Completion | 2010-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00350818
The ClinicalTrials.gov registry entry for NCT00350818 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Azacitidine is the first listed.
NCT00350818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00350818 about?
NCT00350818 is a clinical study titled "Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT)". Primary Objective: -To determine the dose and schedule combination of 5-Azacitidine, when used as maintenance treatment after allogeneic transplantation for high-risk AML / MDS. Secondary Objective: -To assess the effect of treatment on survival after allogeneic transplantation for high-risk AML ...
What is the current status of trial NCT00350818?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2005-10. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00350818?
The interventions under investigation include: Azacitidine (DRUG).
Who is sponsoring clinical trial NCT00350818?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.